1. Home
  2. BBAR vs LQDA Comparison

BBAR vs LQDA Comparison

Compare BBAR & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BBAR

Banco BBVA Argentina S.A. ADS

HOLD

Current Price

$16.81

Market Cap

3.1B

Sector

Finance

ML Signal

HOLD

LQDA

Liquidia Corporation

HOLD

Current Price

$37.80

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BBAR
LQDA
Founded
1886
2004
Country
Argentina
United States
Employees
N/A
N/A
Industry
Commercial Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
3.1B
IPO Year
1997
2020

Fundamental Metrics

Financial Performance
Metric
BBAR
LQDA
Price
$16.81
$37.80
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
11
Target Price
$17.00
$41.00
AVG Volume (30 Days)
586.3K
1.1M
Earning Date
05-20-2026
05-07-2026
Dividend Yield
1.76%
N/A
EPS Growth
N/A
51.81
EPS
N/A
N/A
Revenue
N/A
$158,320,000.00
Revenue This Year
$18.32
$278.87
Revenue Next Year
$11.04
$57.13
P/E Ratio
$26.78
N/A
Revenue Growth
N/A
1031.18
52 Week Low
$7.76
$11.85
52 Week High
$23.10
$46.67

Technical Indicators

Market Signals
Indicator
BBAR
LQDA
Relative Strength Index (RSI) 61.12 49.78
Support Level $16.71 $31.75
Resistance Level $17.14 $39.19
Average True Range (ATR) 0.76 2.12
MACD 0.14 0.09
Stochastic Oscillator 94.95 37.52

Price Performance

Historical Comparison
BBAR
LQDA

About BBAR Banco BBVA Argentina S.A. ADS

Banco BBVA Argentina SA is a banking services provider in Argentina. It provides financial assistance to large corporations, small and medium-sized companies, as well as individuals. It bank provides services through retail, corporate, investment banking, and Small and medium-sized companies divisions. Through the retail banking segment, it provides banking products and services to individuals, corporate banking deals with services to corporates, and the small and medium-sized companies segment focuses on foreign trade, agricultural business, and digital products.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Share on Social Networks: